LT4010322T - (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil- 1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamido kieto pavidalo formos ir jų panaudojimas - Google Patents

(s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil- 1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamido kieto pavidalo formos ir jų panaudojimas

Info

Publication number
LT4010322T
LT4010322T LTEPPCT/US2019/045948T LTUS2019045948T LT4010322T LT 4010322 T LT4010322 T LT 4010322T LT US2019045948 T LTUS2019045948 T LT US2019045948T LT 4010322 T LT4010322 T LT 4010322T
Authority
LT
Lithuania
Prior art keywords
neopentylamino
pentanamide
tetrahydronaphthalen
propan
imidazol
Prior art date
Application number
LTEPPCT/US2019/045948T
Other languages
English (en)
Inventor
Elaine Greer
Stephen Anderson
Mark MALONEY
Shu Yu
Ekaterina Albert
Emily Rigsbee
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of LT4010322T publication Critical patent/LT4010322T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LTEPPCT/US2019/045948T 2019-08-09 2019-08-09 (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil- 1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamido kieto pavidalo formos ir jų panaudojimas LT4010322T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/045948 WO2021029854A1 (en) 2019-08-09 2019-08-09 Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Publications (1)

Publication Number Publication Date
LT4010322T true LT4010322T (lt) 2025-12-29

Family

ID=67734850

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/045948T LT4010322T (lt) 2019-08-09 2019-08-09 (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil- 1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamido kieto pavidalo formos ir jų panaudojimas

Country Status (21)

Country Link
EP (2) EP4722197A1 (lt)
JP (1) JP7608435B2 (lt)
KR (1) KR102772889B1 (lt)
CN (1) CN114555562A (lt)
AR (1) AR119614A1 (lt)
AU (1) AU2019461090B2 (lt)
BR (1) BR112022002392A2 (lt)
CA (1) CA3150424A1 (lt)
CO (1) CO2022002731A2 (lt)
DK (1) DK4010322T3 (lt)
FI (1) FIC20260011I1 (lt)
HR (1) HRP20251641T1 (lt)
IL (1) IL290428A (lt)
LT (1) LT4010322T (lt)
MX (1) MX2022001743A (lt)
NL (1) NL301374I2 (lt)
NO (1) NO2026017I1 (lt)
PE (1) PE20221252A1 (lt)
PT (1) PT4010322T (lt)
RS (1) RS67562B1 (lt)
WO (1) WO2021029854A1 (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916188A (zh) * 2020-03-13 2023-04-04 斯普林渥克斯治疗有限公司 尼罗司他与bcma定向疗法的组合疗法及其用途
MX2024002590A (es) 2021-09-01 2024-03-22 Springworks Therapeutics Inc Sintesis de nirogacestat.
US11504354B1 (en) * 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
EP4436958A1 (en) 2021-11-23 2024-10-02 Teva Pharmaceuticals International GmbH Solid state forms of nirogacestat salts
WO2023174390A1 (zh) * 2022-03-17 2023-09-21 苏州科睿思制药有限公司 尼罗司他二氢溴酸盐的晶型及其制备方法和用途
JP2026508907A (ja) 2023-03-09 2026-03-13 ▲蘇▼州科睿思制▲葯▼有限公司 ニロガセスタット二臭化水素酸塩の結晶形、及びその調製方法並びに用途
WO2026018210A1 (en) 2024-07-19 2026-01-22 Assia Chemical Industries Ltd. Solid state forms of nirogacestat dihydrochloride salt

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2379A (en) 2004-03-23 2012-03-08 Pfizer Prod Inc Imidazole compounds for the treatment of neurodegenerative disorders.
WO2015092614A1 (en) 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
WO2019053727A1 (en) * 2017-09-18 2019-03-21 Ramot At Tel-Aviv University Ltd. REDIFFERENCING IN VITRO DEVELOPED CELLS FROM HUMAN PANCREATIC ISLAND BEA CELLS ADULPTED BY SMALL MOLECULE INHIBITORS OF THE SIGNALING PATH

Also Published As

Publication number Publication date
CN114555562A (zh) 2022-05-27
MX2022001743A (es) 2022-05-10
BR112022002392A2 (pt) 2022-04-26
PE20221252A1 (es) 2022-08-16
EP4010322B1 (en) 2025-11-05
EP4010322A1 (en) 2022-06-15
NL301374I2 (nl) 2026-07-13
AR119614A1 (es) 2021-12-29
CO2022002731A2 (es) 2022-05-20
HRP20251641T1 (hr) 2026-02-13
AU2019461090A1 (en) 2022-03-17
EP4722197A1 (en) 2026-04-08
PT4010322T (pt) 2025-12-16
KR102772889B1 (ko) 2025-02-26
AU2019461090B2 (en) 2026-06-18
JP2022553479A (ja) 2022-12-23
IL290428A (en) 2022-07-01
RS67562B1 (sr) 2026-01-30
FIC20260011I1 (fi) 2026-04-07
WO2021029854A1 (en) 2021-02-18
KR20220062510A (ko) 2022-05-17
JP7608435B2 (ja) 2025-01-06
NO2026017I1 (no) 2026-03-26
DK4010322T3 (da) 2025-12-15
CA3150424A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
SI4010322T1 (sl) Trdne oblike (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol- 4-il)pentanamida in njegova uporaba
PT4010322T (pt) Formas no estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4- tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1- (neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e suas utilizações
IL281024A (en) Pharmaceutical preparations containing N–(3,5–DIMETHOXYPHENYL)–N'–(1–METHYLETHYL)–N–[3–(1–METHYL–1H–PYRAZOL–4–YL)QUINOXALIN–6–YL]ETHANE–1, 2-DIAMINE
ZA202211870B (en) Imidazolidinone derivatives and medical use thereof
IL288996B2 (en) Aminopyrimidine amide autophagy inhibitors and methods of using them
EP1608361A4 (en) COMPOSITIONS OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS AND 5-HT1B / 1 D AGONISTS FOR THE TREATMENT AND PREVENTION OF MIGRAINS
IL276823A (en) Casein formulations and their use
MX370099B (es) Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
IL310209A (en) ROCK2 inhibitors and their uses
IL264854A (en) Spt5 inhibitors and methods of use thereof
MX2020005771A (es) Composicion y metodo para tratar el linfoma periferico de linfocitos t y el linfoma cutaneo de linfocitos t.
IL290087B2 (en) Modified aminoheteroaryls and their use as DES1 inhibitors and/or antifibrotic agents
MX2024002590A (es) Sintesis de nirogacestat.
IL305789A (en) USP30 inhibitors and uses thereof
IL313081A (en) New HDAC inhibitors and their medical use
IL311733A (en) Hydrochloride salt of inupdanant, pharmaceutical preparations and methods of using it
EP3843742A4 (en) CD73 INHIBITORS AND THEIR THERAPEUTIC USES
WO2021080931A8 (en) Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
ZA201600006B (en) Polymorphic forms of methyl((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof
EP3844289A4 (en) COMPOSITION AND USE OF CAS PROTEIN INHIBITORS
MX2020007494A (es) Formulaciones orales de metronidazol y metodos de tratamiento de una infeccion con las mismas.
HK40111933A (en) Rock2 inhibitors and uses thereof
HUP2300462A1 (hu) Imidazol-származékok és alkalmazásuk antifibrotikus szerként
HK40077223A (en) Equine esomeprazole formulations and methods of use
HK1242618A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine